Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
Noll Campbell1, Amir Ayub2, Malaz A Boustani2, Chris Fox3, Martin Farlow4, Ian Maidment3, Robert Howard5
1Wishard Health Services, Indianapolis, Indiana; 2Indiana University Center for Aging Research, Regenstrief Institute, Inc., Indianapolis, Indiana; 3University of Kent, Kent, United Kingdom; 4Indiana University School of Medicine, Indianapolis, Indiana; 5King’s College, London, United Kingdom
Objective: To determine the efficacy of cholinesterase inhibitors (ChEIs) in improving the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer’s disease (AD).
Data sources: We searched MEDLINE, Cochrane Registry, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 1966 to 2007. We limited our search to English Language, full text, published articles and human studies.
Data extraction: We included randomized, double-blind, placebo-controlled trials evaluating the efficacy of donepezil, rivastigmine, or galantamine in managing BPSD displayed by AD patients. Using the United States Preventive Services Task Force (USPSTF) guidelines, we critically appraised all studies and included only those with an attrition rate of less than 40%, concealed measurement of the outcomes, and intention to treat analysis of the collected data. All data were imputed into pre-defined evidence based tables and were pooled using the Review Manager 4.2.1 software for data synthesis.
Results: We found 12 studies that met our inclusion criteria but only nine of them provided sufficient data for the meta-analysis. Among patients with mild to severe AD and in comparison to placebo, ChEIs as a class had a beneficial effects on reducing BPSD with a standard mean difference (SMD) of −0.10 (95% confidence interval [CI]; −0.18, −0.01) and a weighted mean difference (WMD) of −1.38 neuropsychiatry inventory point (95% CI; −2.30, −0.46). In studies with mild AD patients, the WMD was −1.92 (95% CI; −3.18, −0.66); and in studies with severe AD patients, the WMD was −0.06 (95% CI; −2.12, +0.57).
Conclusion: Cholinesterase inhibitors lead to a statistical significant reduction in BPSD among patients with AD, yet the clinical relevance of this effect remains unclear.
Keywords: Alzheimer’s disease, dementia, cholinesterase inhibitors, behavioral and psychological symptoms
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Other articles by this author:
Selecting a change and evaluating its impact on the performance of a complex adaptive health care delivery system
Malaz A Boustani, Stephanie Munger, Rajesh Gulati, et al
Published Date: 5 May 2010
Noll Campbell, Malaz Boustani, Tony Limbil, Carol Ott, et al.
Published Date: 13 May 2009
Malaz Boustani, Cathy Schubert, Youcef Sennour
Published Date: 15 January 2008
Readers of this article also read:
Relationship between serum cardiac troponin T level and cardiopulmonary function in stable chronic obstructive pulmonary disease
Hattori K, Ishii T, Motegi T, Kusunoki Y, Gemma A, Kida K
Published Date: 10 February 2015
Tomuleasa C, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A
Published Date: 11 February 2014
Mielke MM, Vemuri P, Rocca WA
Published Date: 8 January 2014
Vandooren J, Berghmans N, Dillen C, Van Aelst I, Ronsse I, Israel LL, Rosenberger I, Kreuter J, Lellouche JP, Michaeli S, Locatelli E, Comes Franchini M, Aiertza MK, Sánchez-Abella L, Loinaz I, Edwards DR, Shenkman L, Opdenakker G
Published Date: 13 December 2013
Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138– CD34– tumor stem-like cells in multiple myeloma-bearing mice
Yang C, Wang J, Chen D, Chen J, Xiong F, Zhang H, Zhang Y, Gu N, Dou J
Published Date: 12 April 2013
Salleh SH, Hussain HS, Swee TT, Ting CM, Noor AM, Pipatsart S, Ali J, Yupapin PP
Published Date: 11 June 2012
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
Published Date: 5 December 2008
Inja Bogdan Allemann, Leslie Baumann
Published Date: 5 December 2008
Stuart C McBain, Humphrey HP Yiu, Jon Dobson
Published Date: 6 June 2008
Kevin P Newman, Syamal K Bhattacharya, Ahmad Munir, Richard C Davis, Judith E Soberman, et al
Published Date: 15 November 2007